From Indonesia’s all-out halal regulations to sodium policies spurring rapid reformulation and taxation changes affecting ...
NEW YORK – The European Commission has approved a high-dose regimen of Biogen's Spinraza (nusinersen), an antisense oligonucleotide for 5q spinal muscular atrophy (SMA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback